Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388421 · ClinicalTrials.gov registry record
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A clinical trial of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by United Therapeutics.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 20
- Study locations
NCT06388421 is a study of Pulmonary Hypertension and Interstitial Lung Disease that is actively recruiting participants, run by United Therapeutics. The registered enrollment target is 1,000 participants, above the 600-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (67% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06388421, a study of Pulmonary Hypertension and Interstitial Lung Disease, is actively recruiting participants, sponsored by United Therapeutics.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Conditions Studied
Interventions
- OTHER Prospective study assessments
Study Locations (20)
Florida
- University of Florida - Gainesville
- NCH Research Institute - Naples
- Advent Health Medical Group Advanced Lung Disease - Orlando
- Intercoastal Medical Group - Sarasota
- Tampa General Hospital/University of South Florida Health - Tampa
Illinois
- Northwestern University - Chicago
- Loyola University Medical Center - Maywood
- Advocate Christ Medical Center - Oak Lawn
Colorado
- University of Colorado - Anschutz Medical Campus - Aurora
- National Jewish Health - Denver
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Banner Health - University Medical Center Phoenix - Phoenix
Georgia
- Emory University - Atlanta
Indiana
- Ascension St. Vincent - Indianapolis
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2030-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06388421
The ClinicalTrials.gov registry entry for NCT06388421 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 600-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (67% higher). The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Prospective study assessments is the first listed.
NCT06388421 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Illinois, Colorado.
Frequently Asked Questions
What is clinical trial NCT06388421 about?
NCT06388421 is a clinical study titled "DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)". This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
What is the current status of trial NCT06388421?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-01-23. Estimated completion is 2030-11-30.
What conditions does trial NCT06388421 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Interstitial Lung Disease, Pulmonary Hypertension Due to Lung Diseases and Hypoxia.
What interventions are being tested in trial NCT06388421?
The interventions under investigation include: Prospective study assessments (OTHER).
Who is sponsoring clinical trial NCT06388421?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06388421 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
RECRUITING
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.